Back to Journals » Drug Design, Development and Therapy » Volume 13

Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report

Authors Mao S, Zhang J, Guo Y, Zhang Z, Wu Y, Zhang W, Wang L, Jiang Geng, Yan Y, Yao X

Received 17 September 2018

Accepted for publication 19 December 2018

Published 11 January 2019 Volume 2019:13 Pages 291—300

DOI https://doi.org/10.2147/DDDT.S181122

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Qiongyu Guo


Shiyu Mao,1,* Junfeng Zhang,1,* Yadong Guo,1,* Ziwei Zhang,1 Yuan Wu,2 Wentao Zhang,2 Longsheng Wang,1 Jiang Geng,1 Yang Yan,1 Xudong Yao1

1Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, PR China; 2Department of Urology, Shanghai Tenth People’s Hospital, Anhui Medical University, Hefei 230032, PR China

*These authors contributed equally to this work

Background: Immune checkpoint blockade targeting programmed cell death ligand-1 (PD-L1)/programmed death-1 (PD-1) signaling was approved recently for locally advanced and metastatic urothelial bladder carcinoma (UBC). Some patients experience a very rapid tumor progression, rather than clinical benefit, from anti-PD-L1/PD-1 therapy.
Case presentation: A 58-year-old male diagnosed with non-muscle-invasive bladder cancer 3 years ago received transurethral resection of bladder tumor (TURBT) and intravesical chemotherapy. TURBT was repeated a year later for recurrent and progressive UBC. Following further disease progression, he received a radical cystectomy (RC), pathologically staged as T2bN2M0, and adjuvant cisplatin-containing combination chemotherapy. When his disease progressed to metastatic UBC, he was started on anti-PD-L1 monotherapy and experienced ultrarapid disease progression within 2 months; imaging scans ruled out pseudoprogression. We observed a fourfold increase in tumor growth rate, defined as the ratio of post- to pretreatment rates. Next-generation sequencing of formalin-fixed paraffin-embedded RC tissues showed MDM2 amplification without MDM4 amplification, EGFR aberrations, or DNMT3A alterations. Immunohistochemistry showed grade 2+ PD-L1 labeling intensity of the RC tissues, with 15%–25% and 5%–10% PD-LI immunopositive tumor cells and tumor-infiltrating immune cells, respectively.
Conclusion: Even in cases with PD-L1-positive tumors, MDM2 gene amplification may result in failure of anti-PD-L1 immunotherapy and rapid tumor growth. Therefore, genomic profiling may identify patients at risk for hyperprogression before immunotherapy.

Keywords: urothelial bladder carcinoma, programmed cell death ligand-1, immune checkpoint blockade, hyperprogression, MDM2
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]